Repligen Reports Record Q3 Revenue and Raises 2026 Guidance Following BioLife Acquisition
Repligen (RGEN) reported a record-breaking third quarter with revenue reaching $209 million. Driven by strong operational performance, the company has officially increased its guidance for the 2026 fiscal year. The company also confirmed the successful closing of its acquisition of BioLife earlier this month. Looking ahead, management signaled long-term growth targets, aiming for at least 25% top-line growth through 2027 and projecting total revenue to exceed $1 billion.
Tickers: $RGEN
Topics: acquisition earnings report guidance increase revenue growth